Core Viewpoint - The report from Citi Research indicates that WuXi AppTec (02359.HK) is expected to achieve a 9% revenue growth and a 36% increase in adjusted net profit for Q4 2025, surpassing market expectations by 2% and 3% respectively, driven by its strong integrated CRDMO model and robust growth in its WuXi TIDES business, along with China's competitive advantage in the global small molecule supply chain [1] Group 1 - The strong performance of WuXi AppTec is attributed to its comprehensive CRDMO model and the significant growth of its WuXi TIDES business [1] - The company is expected to outperform the market, with adjusted net profit growth projected to be in the high double digits (approximately 16% to 19%) for 2026, exceeding the market expectation of 15% [1] - Citi Research maintains its forecasts for 2025 to 2027 and has set a target price of HKD 143.4 for WuXi AppTec, designating it as a preferred stock in the Chinese CRO/CDMO sector [1]